Pain News and Research

Latest Pain News and Research

Simcere enters share transfer agreement with Devont Asset Management

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the Company entered into a share transfer agreement with Devont Asset Management Limited on January 15th 2013 to sell an approximately 35% equity interest in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. for a cash consideration of RMB 302 million.

22 Jan 2013

Russia approves FzioMed’s Oxiplex gel for lumbar spine surgery

FzioMed, a privately held medical device company based in San Luis Obispo, CA., is pleased to announce the approval of Oxiplex in Russia. Oxiplex is an absorbable, clear, viscoelastic gel that is applied during lumbar spine surgery immediately prior to wound closure.

22 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Study reveals ugly cholesterol is the direct cause of ischaemic heart disease

The risk of ischaemic heart disease - a disease affecting some 150,000 Danes - is three times higher in persons with high levels of the so-called 'ugly' cholesterol. This is the finding of a new study of 73,000 Danes, which is shedding light on a long debate on this topic. The results have just been published in the Journal of the American College of Cardiology.

22 Jan 2013

Knee replacement pain predicted by comorbidity

Research may help physicians give patients undergoing total knee arthroplasty a realistic expectation of surgery outcome based on their overall physical and mental health, US researchers believe.

21 Jan 2013

Parental depression linked to TMD pain in young adults

A mother’s depression during pregnancy is not a risk factor for temporomandibular disorders in her child, a 31-year follow-up study indicates.

21 Jan 2013

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch was actually defined by a German physician more than 350 years ago. His name was Samuel Hafenreffer. He defined itch as an unpleasant sensation that makes people want to scratch. You probably think this is a very simple definition but itch is really a very complex sensory modality.

21 Jan 2013

Researchers identify clear role for tags in mediating genetic risk for rheumatoid arthritis

In one of the first genome-wide studies to hunt for both genes and their regulatory "tags" in patients suffering from a common disease, researchers have found a clear role for the tags in mediating genetic risk for rheumatoid arthritis (RA), an immune disorder that afflicts an estimated 1.5 million American adults.

21 Jan 2013

New study: Loneliness can harm overall health

New research links loneliness to a number of dysfunctional immune responses, suggesting that being lonely has the potential to harm overall health.

20 Jan 2013

Nurse practitioners, certified midwives and PAs can provide safe early abortion care

First trimester abortions are just as safe when performed by trained nurse practitioners, physician assistants and certified nurse midwives as when conducted by physicians, according to a new six-year study led by UCSF.

19 Jan 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

St. Jude Medical’s AMPLATZER Amulet device receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its AMPLATZER Amulet Left Atrial Appendage Occluder.

19 Jan 2013

NSU to host conference on neuro immune conditions

Nova Southeastern University (NSU) will be hosting a conference on Saturday, Jan. 26 about the upcoming opening of the NSU College of Osteopathic Medicine's Institute for Neuro Immune Medicine.

19 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Calcium receptor – potential drug target for sleeping sickness

While its common name may make it sound almost whimsical, sleeping sickness, or African trypanosomiasis, is in reality a potentially fatal parasitic infection that has ravaged populations in sub-Saharan Africa for decades, and it continues to infect thousands of people every year.

19 Jan 2013

Rite Aid obtains more than 400,000 additional seasonal flu shots

In response to the nationwide flu epidemic and customer demand, Rite Aid Corporation announced today it has obtained more than 400,000 additional seasonal flu shots, which began arriving in stores earlier this week.

19 Jan 2013

JNS publishes data from Providence’s DTRAX Facet Screw System clinical study

Providence Medical Technology, Inc. today announced the publication of the first peer-reviewed clinical paper describing the outcomes of the DTRAX Facet Screw System.

19 Jan 2013

Botulinum toxin A more effective than intralesional steroids in treating plantar fasciitis

Plantar fasciitis is the most frequent cause of chronic heel pain, leaving many sufferers unable to put their best foot forward for months at a time. Now a Mexican study suggests that physicians should turn to Botox rather than steroids to offer patients the fastest road to recovery.

18 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Health Canada approves Forest Laboratories’ BYSTOLIC to treat hypertension

Forest Laboratories, Inc. announced today that its Canadian subsidiary, Forest Laboratories Canada Inc. has received a Notice of Compliance from Health Canada for BYSTOLIC (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.

18 Jan 2013